1. Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15-44: United States 2011-2013. NCHS data brief, no. 173 . Hyattsville, MD: National Center for Health Statistics, 2014.
2. Branum AM, Jones J. Trends in long-acting reversible contraception use among US women aged 15-44. NCHS data brief, no. 188 . Hyattsville, MD: National Center for Health Statistics, 2015.
3. Centers for Disease Control and Prevention (CDC). US medical eligibility criteria for contraceptive use, 2010. MMWR Recomm Rep . 2010;59:1-86.
4. American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No 121: Long-acting reversible contraception: Implants and intrauterine devices. Obstet Gynecol . 2011;118:184-196.
5. Pickle S, Wu J, Burbank-Schmitt E. Prevention of unintended pregnancy: a focus on long-acting reversible contraception. Prim Care . 2014;41:239-260.
6. Winner B, Peipert JF, Zhao Q, et al. Effectiveness of long-acting reversible contraception. N Engl J Med . 2012;366:1998-2007.
7. Peipert JF, Zhao Q, Allsworth JE, et al. Continuation and satisfaction of reversible contraception. Obstet Gynecol . 2011;117:1105-1113.
8. O’Neil-Callahan M, Peipert JF, Zhao Q, et al. Twenty-four-month continuation of reversible contraception. Obstet Gynecol . 2013;122:1083-1091.
9. Grunloh DS, Casner T, Secura GM, et al. Characteristics associated with discontinuation of long-acting reversible contraception within the first 6 months of use. Obstet Gynecol . 2011;117:705-719.
10. Birgisson NE, Zhao Q, Secura GM, et al. Preventing unintended pregnancy: the contraceptive CHOICE project in review. J Womens Health (Larchmt) . 2015;24:349-353.
11. ParaGard T 380A. (intrauterine copper contraceptive) [package insert]. Sellersville, PA : Teva Pharmaceuticals USA, Inc., 2013.
12. Skyla (levonorgestrel-releasing intrauterine system) [package insert]. Wayne, NJ : Bayer HealthCare Pharmaceuticals, Inc., 2013.
13. Liletta (levonorgestrel-releasing intrauterine system) [package insert]. Parsippany, NJ : Actavis Pharma, Inc., 2015.
14. Mirena (levonorgestrel-releasing intrauterine system) [package insert]. Whippany, NJ : Bayer HealthCare Pharmaceuticals, Inc., 2014.
15. Nexplanon (etongestrel implant) [package insert]. Whitehouse Station, NJ: Merck & Co Inc.; 2014.
16. Wu JP, Pickle S. Extended use of the intrauterine device: a literature review and recommendations for clinical practice. Contraception . 2014;89:495-503.
17. Stoddard A, McNicholas C, Peipert JF. Efficacy and safety of long-acting reversible contraception. Drugs . 2011;71:969-980.
18. Xu H, Wade JA, Peipert JF, et al. Contraceptive failure rates of etonogestrel subdermal implants in overweight and obese women. Obstet Gynecol . 2012;120:21-26.
19. Centers for Disease Control and Prevention (CDC). US selected practice recommendations for contraceptive use. MMWR Recomm Rep . 2013;62:1-60.
20. Centers for Disease Control and Prevention (CDC). Sexually transmitted disease treatment guidelines. MMWR Recomm Rep . 2010;59:1-110.
21. Gurtcheff SE, Turok DK, Stoddard G, et al. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol . 2011;117:1114-1121.
22. Chen BA, Reeves MF, Creinin MD, et al. Postplacental or delayed levonorgestrel intrauterine device insertion and breast-feeding duration. Contraception . 2011;84:499-504.
23. Heinemann K, Reed S, Moehner S, et al. Risk of uterine perforation with levonorgestrel-releasing and copper intrauterine devices in the European Active Surveillance Study on Intrauterine Devices. Contraception . 2015;91:274-279.
24. Tocce K, Sheeder J, Python J, et al. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting. J Pediatr Adolesc Gynecol . 2012;25:59-63.
25. Mwalwanda CS, Black KI. Immediate post-partum initiation of intrauterine contraception and implants: a review of the safety and guidelines for use. Aust N Z J Obstet Gynaecol . 2013;53:331-337.
26. Sober, S, Schreiber CA. Postpartum contraception. Clin Obstet Gynecol . 2014;57:763-776.
27. Dickerson LM, Diaz VA, Jordon J, et al. Satisfaction, early removal, and side effects associated with long-acting reversible contraception. Fam Med . 2013;45:701-707.
28. Berenson AB, Tan A, Hirth JM. Complications and continuation rates associated with 2 types of long-acting contraception. Am J Obstet Gynecol . 2015;212:e1-e8.
29. Kavanaugh ML, Frowirth L, Jerman J, et al. Long-acting reversible contraception for adolescents and young adults: patient and provider perspectives. J Pediatr Adolesc Gynecol . 2013;86:86-95.
30. Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol . 2011;117:705-719.
31. Madden T, McNicholas C, Zhao Q, et al. Association of age and parity with intrauterine device expulsion. Obstet Gynecol . 2014;124:718-726.
